Tudor Investment Corp
VTGN icon

Tudor Investment Corp’s VistaGen Therapeutics VTGN Stock Holding History

Tudor Investment Corp’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.7K Buy
106,172
+30,000
+39% +$18.2K ﹤0.01% 3489
2025
Q4 		$50.4K Buy
+76,172
New +$275K ﹤0.01% 3395

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tudor Investment Corp's VTGN Position: Q1 2026 in Review

Tudor Investment Corp increased its VistaGen Therapeutics (VTGN) stake by 39% in Q1 2026, buying an estimated $18.2K and bringing the position to 106,172 shares worth $60.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3489.

Tudor Investment Corp first reported a position in VTGN in Q4 2025 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Tudor Investment Corp held 106,172 shares of VistaGen Therapeutics worth $60.7K as of Q1 2026.
  • Tudor Investment Corp bought 30,000 VistaGen Therapeutics shares in Q1 2026, an estimated $18.2K.
  • VistaGen Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #3489 holding.
  • Tudor Investment Corp first reported a position in VistaGen Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.